Andere talen GC Biopharma Corp.

Aandelen

A006280

KR7006280002

slotkoers Korea S.E. Andere beurzen 00:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
114.600 ^KRW	+0,44%		-0,95%	-8,69%

03/05	Green Cross vergroot verlies over eerste kwartaal, omzet stijgt met 2%	MT
20/03	GC Biopharma Corp. Rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Green Cross Widens Q1 Loss, Sales Inch Up 2%	03/05
GC Biopharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
GC Biopharma Corp. Announces US FDA Approval for ALYGLO (Immune Globulin Intravenous, Human-Stwk) 10% Liquid for Adults with Primary Humoral Immunodeficiency (PI)	18/12
GC Biopharma Establishes mRNA Production Facility in Hwasun, Korea	01/12
GC Biopharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
GC Biopharma Applies for MFDS Approval	06/11
Immetas Therapeutics and GC Biopharma Announces Research Collaboration to Discover and Develop mRNA Therapeutics to Treat Autoimmune Diseases	12-10-23
GC Biopharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14-08-23
Green Cross's Net Income Plunges in Q2	02-08-23
GC Biopharma's "GC FLU" Obtains Vaccine Approval in Egypt	21-07-23
GC Biopharma's "GC FLU" obtains vaccine approval in Egypt: First-ever approval of the company's quadrivalent flu vaccine on the African continent	19-07-23
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia	02-06-23
GC Biopharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15-05-23
Green Cross Swings to Loss in Q1	03-05-23
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates	01-03-23
GC Biopharma Receives WHO Pre-Qualification for BARYCELA	20-02-23
GC Biopharma Receives WHO Pre-Qualification for Filling and Finish Plant in Ochang, South Korea	09-02-23
Curevo, Inc. announced that it has received $22.000002 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, GC Biopharma Corp. and other investors	21-11-22
Green Cross Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14-11-22
Curevo, Inc. announced that it expects to receive $26.000003 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Adjuvant Capital, LP, Green Cross Corporation	09-11-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen GC Biopharma Corp.

Aandelen

A006280

KR7006280002

Andere talen

Filters